003000 — Bukwang Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Bukwang Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	182,491	190,909	125,928	160,087	200,714
Cost of Revenue
Gross Profit	75,758	79,429	47,074	74,343	91,910
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	176,869	191,140	164,151	160,599	189,474
Operating Profit	5,622	-231	-38,223	-512	11,240
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,787	-1,033	-39,569	-2,970	6,386
Provision for Income Taxes
Net Income After Taxes	-2,797	-4,249	-34,407	-3,459	12,433
Minority Interest
Net Income Before Extraordinary Items
Net Income	-917	-2,475	-31,330	-2,641	12,558
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-917	-2,475	-31,330	-2,641	12,558
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-14	-33.1	-412	-17.2	172
Dividends per Share